6don MSN
Ionis Pharmaceuticals repriced drug ahead of key FDA decision, signals push into larger market
On Wednesday, Ionis Pharmaceuticals Inc. IONS said it is cutting the annual list price of its triglyceride-lowering drug ...
14don MSN
Why Ionis Pharmaceuticals’ (IONS) 2026 Catalyst Pipeline Supported Leerink’s Higher Target
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best growth stocks to buy according to billionaires. As of March 13, 2026, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) carried a Moderate Buy ...
In the latest quarter, 6 analysts provided ratings for Ionis Pharmaceuticals (NASDAQ:IONS), showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their ...
Yaron Werber, an analyst from TD Cowen, maintained the Buy rating on Ionis Pharmaceuticals (IONS – Research Report). The associated price target remains the same with $59.00. Yaron Werber has given ...
On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and ...
Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ...
Ionis Pharma projects $2B+ peak revenue for Olezarsen, which is highly conservative given the U.S. addressable market. Read ...
The Ionis Pharmaceuticals Inc.-Bond has a maturity date of 4/1/2026 I18N_bonds#descriptiontext#couponpart#undefinedcoupon The Ionis Pharmaceuticals Inc.-Bond was ...
Case Western Reserve University and Ionis Pharmaceuticals Inc. have signed an exclusive license agreement to advance and commercialize a therapeutic approach discovered by university medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results